Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | VCP | P55072 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26263767 | 0.96 | HRH3 (0.50) | HRH3KCNH2CYP2D6CHRM3DRD2 | |
| SCHEMBL26295658 | 0.92 | HRH3 (0.47) | HRH3KCNH2CYP2D6CHRM3DRD2 | |
| SCHEMBL26295653 | 0.89 | HRH3 (0.53) | HRH3KCNH2CYP2D6GNAI3GNAO1 | |
| SCHEMBL26295651 | 0.89 | CHRM3 (0.40) | HRH3KCNH2CYP2D6CHRM3DRD2 | |
| SCHEMBL26295662 | 0.88 | HRH3 (0.48) | HRH3KCNH2CYP2D6CHRM3DRD2 | |
| SCHEMBL26295640 | 0.88 | HRH3 (0.55) | HRH3KCNH2CYP2D6CHRM3 | |
| SCHEMBL26295663 | 0.86 | HRH3 (0.50) | HRH3KCNH2CYP2D6GNAI3GNAO1 | |
| SCHEMBL26295656 | 0.85 | HRH3 (0.52) | HRH3KCNH2CYP2D6CHRM3 | |
| SCHEMBL26295685 | 0.85 | HRH3 (0.43) | HRH3KCNH2CYP2D6DRD2DRD3 | |
| SCHEMBL26494065 | 0.84 | HRH3 (0.39) | HRH3VCPGNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295118-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES | ENDOTARGET INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295118-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES | ENDOTARGET INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295118-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES | CDK6, CDK4, CDK1 | HRH3 2877/4885KCNH2 4819/4885CYP2D6 618/4885 |
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, BCL9, CRBN | HRH3 3222/4885KCNH2 4681/4885CYP2D6 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.